Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on May 05, 2023 3:29pm
232 Views
Post# 35433676

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Partnerships...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Partnerships...Quentin,

It is not a surprise that OS is not going to be available yet. Matt outlined the numbers, and confirmed that we need 80% of them to pass in order to get the OS results. That is in the future. 

You are right that the addition of a CPI may or may not occur. But I do not think we "lost" five years because of that. At the time, five years back, that is what our interested partner, Pfizer wanted. So we needed them to proceed to a registration study. I expect we did not have that without doing this interim trial. If we did, they would have proceeded back then.  


Aside from that reasoning, if we had proceeded five years back, we would most likely not have developed the panc and CAR-T opportunities we have in front of us now.

You indicate you own 35000 shares. Then why do you complain about what the company is doing, particularly since it is going well?
<< Previous
Bullboard Posts
Next >>